EIF5B /mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma

BACKGROUND Although eukaryotic translation initiation factor 5B (EIF5B ) is implicated in the pathogenesis of multiple malignancies, its functional impact in colonic adenocarcinoma (COAD) is still not well defined. AIM To determine EIF5B ’s role, mechanisms, and therapeutic associations in COAD. METHODS To assess the prognostic value of EIF5B , we integrated pan-cancer bioinformatic screening with clinical validation in COAD cohorts. The oncogenic function and molecular regulations were evaluated through in vitro and in vivo assays, multi-omic pathway enrichment, Western blotting, rescue experiments, immune infiltration and drug-sensitivity modeling. RESULTS Our results showed significant overexpression of EIF5B in COAD tissues, and its correlation with unfavorable patient outcomes. Functional analysis revealed that EIF5B induced migration, proliferation, and invasion in vitro , as well as promoted tumorigenesis in vivo through phosphorylation of mitogen-activated protein kinase 1 (MAPK1). In addition, the immune microenvironment exhibited a suppressed phenotype, accompanied by decreased predictive scores for programmed cell death protein 1/cytotoxic T lymphocyte-associated antigen-4 blockade and reduced predicted sensitivity to chemotherapeutic agents. EIF5B expression, immune evasion, and drug sensitivity were associated with the MAPK signaling pathway. CONCLUSION EIF5B mediated phosphorylation of MAPK1 regulates the progression of COAD, suggesting EIF5B as potential therapeutic target for overcoming resistance against chemotherapy and immunotherapy.

Authors

Institutions

Publication Details

Journal
World Journal of Gastroenterology
Published
2026-11-21
DOI
https://doi.org/10.3748/wjg.121829
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

EIF5B /mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma

Suliman Khan, Wenhua Li, Na Han, Wenchao Zhao et al.
3 links
World Journal of Gastroenterology
Colorectal Cancer Treatments and Studies
article

EIF5B /mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma

Suliman Khan, Wenhua Li, Na Han, Wenchao Zhao, Qi-Zhong Shi, Yong-Hui Mu, Cheng-Lei Li
article en

Abstract

BACKGROUND Although eukaryotic translation initiation factor 5B (EIF5B ) is implicated in the pathogenesis of multiple malignancies, its functional impact in colonic adenocarcinoma (COAD) is still not well defined. AIM To determine EIF5B ’s role, mechanisms, and therapeutic associations in COAD. METHODS To assess the prognostic value of EIF5B , we integrated pan-cancer bioinformatic screening with clinical validation in COAD cohorts. The oncogenic function and molecular regulations were evaluated through in vitro and in vivo assays, multi-omic pathway enrichment, Western blotting, rescue experiments, immune infiltration and drug-sensitivity modeling. RESULTS Our results showed significant overexpression of EIF5B in COAD tissues, and its correlation with unfavorable patient outcomes. Functional analysis revealed that EIF5B induced migration, proliferation, and invasion in vitro , as well as promoted tumorigenesis in vivo through phosphorylation of mitogen-activated protein kinase 1 (MAPK1). In addition, the immune microenvironment exhibited a suppressed phenotype, accompanied by decreased predictive scores for programmed cell death protein 1/cytotoxic T lymphocyte-associated antigen-4 blockade and reduced predicted sensitivity to chemotherapeutic agents. EIF5B expression, immune evasion, and drug sensitivity were associated with the MAPK signaling pathway. CONCLUSION EIF5B mediated phosphorylation of MAPK1 regulates the progression of COAD, suggesting EIF5B as potential therapeutic target for overcoming resistance against chemotherapy and immunotherapy.

World Journal of GastroenterologyVol. 32(43)
Zhengzhou University (CN), Second Affiliated Hospital of Zhengzhou University (CN), Henan Medical University (CN)
Zhengzhou University
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon